Hidradenitis Suppurativa (Hurley Stage I, Localized)
Investigational adjunct for Hurley stage I localized hidradenitis suppurativa; distinct from Hurley II-III with extensive disease.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for Hidradenitis Suppurativa Hurley Stage I. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). Case reports only. Evidence-based first-line management of Hurley Stage I hidradenitis suppurativa is topical clindamycin, weight loss and smoking cessation, oral tetracyclines for active disease, and adalimumab for moderate-to-severe disease; surgical de-roofing or limited excision for persistent lesions.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Worsening of active inflamed nodules or abscess formation if applied to an actively infected lesion
- Triggering of a draining sinus tract
- Who should not consider this
- Patients with an actively infected, fluctuant abscess (needs incision and drainage plus antibiotics first)
- Patients who have not first tried topical clindamycin, weight management, smoking cessation, or oral tetracycline
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
- People with hemophilia or any other inherited bleeding disorder
- Patients with severe anemia (hemoglobin under 10 g/dL)
- People with an active infection at the planned application site
- Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
- What to ask your clinician
- Has dermatology confirmed I am truly Hurley Stage I and not a higher stage?
- Have I had a full trial of topical clindamycin and an oral tetracycline?
- Is biologic therapy (adalimumab) an option I should explore first?
- What is the evidence base for leech therapy in HS — case reports only?
- What scarring risk does this add to skin that may already scar abnormally?
- How will infection risk be managed since HS lesions can harbor bacteria?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Rapidly expanding redness, fever, severe pain, or red streaks (possible cellulitis or sepsis)
- Sudden purulent drainage with surrounding warmth and fever
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for HS — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace evidence-based HS care: weight management, smoking cessation, topical antibiotics, oral tetracyclines, and biologic therapy.
- It does not stop the underlying chronic inflammatory follicular occlusion process.
- It does not have RCT evidence in any Hurley stage.
- It does not prevent progression from Stage I to higher stages — disease-modifying treatment may.
Safety cross-references
Clinical Profile
- Category
- dermatological
- ICD-10
- L73.2
- Safety tier
- high
Evidence Summary
Hurley stage I HS (single or multiple inflammatory nodules without sinus-tract formation) is conventionally managed with topical clindamycin, intralesional triamcinolone, and oral antibiotics (doxycycline, rifampicin-clindamycin). There is no clinical trial or efficacy case series supporting leech therapy in HS; the only published leech-related report in this condition describes harm (foreign-body granuloma and lymphedema complicating leech therapy). This entry is distinct from the registry's primary HS entry, which addresses broader Hurley I-II disease. If ever considered, sessions would be performed during quiescent intervals only — never on actively draining lesions, given the infection risk. Adalimumab and secukinumab remain primary biologic options for moderate-to-severe disease.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Bhatia S et al. (2020), n=12
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Active draining lesions or abscess
- Hurley stage II or III (extensive sinus tracts)
- Active immunomodulator-induced immunosuppression with neutropenia
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.